Hirotaka Shibata

机构：Astellas Pharma (Japan), Oita University · ORCID：0000-0001-6506-4820

发表论文 365 篇 · 总被引 12139 次 · h-index 43

代表论文

• Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension (2025 · New England Journal of Medicine · 被引 153)
• Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial (2026 · The Lancet · 被引 26)
• Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24 (2025 · Hypertension Research · 被引 17)
• The JSH Morning Hypertension Eradication Program Project (2025 · Hypertension Research · 被引 12)
• Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025 (2025 · Endocrine Journal · 被引 11)
• Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR) (2025 · Cardiovascular Diabetology · 被引 9)